Epistaxis (Nosebleeds) Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
Conditions: Hereditary Hemorrhagic Telangiectasia; Epistaxis Nosebleed Interventions: Drug: Tacrolimus capsule (low-dose); Drug: Placebo Sponsors: St. Michael's Hospital, Toronto; United States Department of Defense Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2020 Category: Research Source Type: clinical trials
